News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
335,607 Results
Type
Article (20271)
Company Profile (130)
Press Release (315206)
Multimedia
Podcasts (75)
Webinars (11)
Section
Business (105753)
Career Advice (881)
Deals (18562)
Drug Delivery (97)
Drug Development (50909)
Employer Resources (79)
FDA (7735)
Job Trends (7779)
News (186445)
Policy (17398)
Tag
Academia (739)
Accelerated approval (3)
Adcomms (17)
Allergies (46)
Alliances (28079)
ALS (60)
Alzheimer's disease (646)
Antibody-drug conjugate (ADC) (102)
Approvals (7745)
Artificial intelligence (153)
Autoimmune disease (17)
Automation (7)
Bankruptcy (177)
Best Places to Work (5569)
BIOSECURE Act (13)
Biosimilars (99)
Biotechnology (58)
Bladder cancer (41)
Brain cancer (19)
Breast cancer (117)
Cancer (1152)
Cardiovascular disease (118)
Career advice (715)
Career pathing (21)
CAR-T (57)
Cell therapy (163)
Cervical cancer (6)
Clinical research (42910)
Collaboration (505)
Compensation (191)
Complete response letters (23)
COVID-19 (1105)
CRISPR (26)
C-suite (166)
Cystic fibrosis (60)
Data (1270)
Decentralized trials (2)
Denatured (19)
Depression (28)
Diabetes (148)
Diagnostics (1826)
Digital health (5)
Diversity (7)
Diversity, equity & inclusion (21)
Drug discovery (83)
Drug pricing (119)
Drug shortages (30)
Duchenne muscular dystrophy (64)
Earnings (39471)
Editorial (34)
Employer branding (10)
Employer resources (73)
Events (49013)
Executive appointments (481)
FDA (8429)
Friedreich's ataxia (3)
Frontotemporal dementia (1)
Funding (337)
Gene editing (53)
Generative AI (18)
Gene therapy (155)
GLP-1 (615)
Government (1877)
Grass and pollen (3)
Guidances (84)
Healthcare (5913)
Huntington's disease (14)
IgA nephropathy (22)
Immunology and inflammation (97)
Indications (19)
Infectious disease (1187)
Inflammatory bowel disease (90)
Inflation Reduction Act (9)
Influenza (25)
Intellectual property (59)
Interviews (116)
IPO (7389)
IRA (45)
Job creations (2442)
Job search strategy (648)
Kidney cancer (7)
Labor market (29)
Layoffs (290)
Leadership (16)
Legal (4135)
Liver cancer (32)
Lung cancer (171)
Lymphoma (95)
Machine learning (5)
Management (30)
Manufacturing (238)
MASH (55)
Medical device (2002)
Medtech (2005)
Mergers & acquisitions (11450)
Metabolic disorders (526)
Multiple sclerosis (52)
NASH (20)
Neurodegenerative disease (54)
Neuropsychiatric disorders (23)
Neuroscience (992)
NextGen: Class of 2025 (2364)
Non-profit (918)
Now hiring (23)
Obesity (329)
Opinion (191)
Ovarian cancer (35)
Pain (76)
Pancreatic cancer (42)
Parkinson's disease (89)
Partnered (12)
Patents (159)
Patient recruitment (52)
Peanut (16)
People (33597)
Pharmaceutical (74)
Pharmacy benefit managers (24)
Phase I (13447)
Phase II (18155)
Phase III (14575)
Pipeline (882)
Policy (135)
Postmarket research (1618)
Preclinical (4719)
Press Release (29)
Prostate cancer (67)
Psychedelics (16)
Radiopharmaceuticals (162)
Rare diseases (255)
Real estate (3179)
Recruiting (29)
Regulatory (12631)
Reports (23)
Research institute (820)
Resumes & cover letters (138)
Rett syndrome (1)
RNA editing (2)
RSV (25)
Schizophrenia (64)
Series A (61)
Series B (37)
Service/supplier (7)
Sickle cell disease (37)
Special edition (16)
Spinal muscular atrophy (111)
Sponsored (12)
Startups (2015)
State (2)
Stomach cancer (9)
Supply chain (55)
Tariffs (55)
The Weekly (54)
Vaccines (289)
Venture capitalists (30)
Weight loss (249)
Women's health (14)
Worklife (8)
Date
Today (61)
Last 7 days (494)
Last 30 days (1615)
Last 365 days (16588)
2025 (6200)
2024 (17707)
2023 (19671)
2022 (25897)
2021 (26679)
2020 (24919)
2019 (20102)
2018 (15617)
2017 (17303)
2016 (16253)
2015 (18864)
2014 (14854)
2013 (12587)
2012 (13504)
2011 (13833)
2010 (12761)
Location
Africa (410)
Alabama (24)
Alaska (1)
Arizona (68)
Arkansas (8)
Asia (25018)
Australia (3237)
California (2779)
Canada (1175)
China (355)
Colorado (107)
Connecticut (106)
Delaware (82)
Europe (51792)
Florida (489)
Georgia (60)
Idaho (16)
Illinois (266)
India (20)
Indiana (182)
Iowa (3)
Japan (133)
Kansas (65)
Kentucky (18)
Louisiana (3)
Maine (4)
Maryland (394)
Massachusetts (2338)
Michigan (49)
Minnesota (147)
Mississippi (1)
Missouri (28)
Montana (10)
Nebraska (11)
Nevada (21)
New Hampshire (8)
New Jersey (1114)
New Mexico (21)
New York (809)
North Carolina (531)
North Dakota (2)
Northern California (1188)
Ohio (84)
Oklahoma (5)
Oregon (21)
Pennsylvania (660)
Puerto Rico (12)
Rhode Island (18)
South America (610)
South Carolina (4)
Southern California (1132)
Tennessee (40)
Texas (364)
United States (11032)
Utah (60)
Virginia (93)
Washington D.C. (47)
Washington State (232)
Wisconsin (25)
335,607 Results for "pact pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neuroscience
GSK Dives Deeper Into Neuro With $2.5B+ ABL Bio Pact
GSK is paying to access ABL Bio’s Grabody-B platform, which potentially enables therapies to cross the blood-brain barrier.
April 7, 2025
·
2 min read
·
Tristan Manalac
Gene therapy
Lilly Throws Sangamo a Lifeline With Pact Worth Potential $1.4B+
Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that in preclinical studies has shown the ability to cross the blood-brain barrier.
April 4, 2025
·
2 min read
·
Tristan Manalac
Legal
Regeneron Sues Sanofi, Alleging Stonewalling in Dupixent Pact
According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent—including agreements with payers and pharmacy benefit managers that determine pricing and rebates for the drug.
February 7, 2025
·
2 min read
·
Tristan Manalac
Weight loss
Roche Makes Another Obesity Play With Potential $5.3B Amylin Pact With Zealand
Roche and Zealand plan to study petrelintide as a monotherapy and in combination with CT-388, a dual agonist of the GLP-1 and GIP receptors that Roche picked up in its recent acquisition of Carmot Therapeutics.
March 12, 2025
·
2 min read
·
Tristan Manalac
Government
Trump Tariffs Miss Pharma For Now, But Uncertainties Loom
Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector-specific duties “in the next month or so.”
April 3, 2025
·
2 min read
·
Tristan Manalac
Compensation
Top 6 Highest-Paid Pharma CEOs in 2024
Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.
April 16, 2025
·
7 min read
·
Annalee Armstrong
Europe
With Tariffs Looming, EU and US Pharmas Make Demands of European Commission
Playing both sides of trade war, pharma companies are asking for certain compensations for scientific innovation and a smoother regulatory framework.
April 16, 2025
·
2 min read
·
Tristan Manalac
Collaboration
Incyte Backs Out of Immuno-Oncology Pact With Agenus
The partnership dates back to 2015, when Incyte paid $60 million upfront for access to four checkpoint programs, including TIM-3, LAG-3, OX40 and GITR.
February 12, 2025
·
2 min read
·
Tristan Manalac
Tariffs
Trump Opens National Security Probe on Pharma Imports, Signaling Imminent Tariffs
Trump could use the findings of the probe to impose certain trade restrictions on pharma products, including tariffs.
April 15, 2025
·
2 min read
·
Tristan Manalac
Deals
M&A, IPOs Snarled by Policy Reality in Q1 as Pharmas Opt for Licensing Deals
M&A and IPOs got off to a quick start in 2025 only to crash into a wall of policy challenges. Upfront payment for licensing transactions, however, grew as pharmas looked for less-risky deals.
May 7, 2025
·
3 min read
·
Annalee Armstrong
1 of 33,561
Next
